Safety of pertussis vaccination in pregnancy and effectiveness in infants: a Danish national cohort study 2019–2023
Clinical Microbiology and Infection · 2025-06 · 31 (6) · 995-1002
DOI: 10.1016/j.cmi.2025.03.014 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Microbiology and Infection, 2025-06. Verfasst von Helene Kildegaard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Denmark. Electronic address: helene.christine.kilde…. Hauptthemen laut MEDLINE: Whooping Cough, Vaccination, Pertussis Vaccine, Vaccine Efficacy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVES: Recent surges in pertussis spread have renewed focus on pertussis vaccination strategies. Denmark implemented pertussis vaccination during pregnancy in 2019 to protect infants under 3 months. This nationwide study assessed the real-world safety and effectiveness of acellular pertussis vaccination during pregnancy. METHODS: Using nationwide Danish registers, we included all pregnancies beyond 24 gestational weeks and all liveborn children from November 1, 2019, to June 1, 2023, with follow-up until December 31, 2023. Maternal safety outcomes included hypertension, preeclampsia, chorioamnionitis, preterm birth, and stillbirth. Infant safety outcomes included neonatal mortality, neonatal intensive care unit admission, and sepsis. Vaccine effectiveness was evaluated against laboratory-confirmed pertussis and related hospital contacts. For maternal safety, vaccinated individuals were matched 1:1 to unvaccinated individuals based on gestational days, calendar week, and region. Infant outcomes were assessed among the cohort of all liveborn children with follow-up until 3 months of age. Analyses were adjusted for a range of demographic, socioeconomic and medical characteristics. RESULTS: Among 50 851 vaccinated and 50 851 unvaccinated individuals during pregnancy, initial analyses showed an increased risk of hypertension and preeclampsia after pertussis vaccination. However, after adjusting for influenza and COVID-19 vaccination during pregnancy, pertussis vaccination was not associated with increased risks of any maternal safety outcomes including hypertension (incidence rate ratio 0.98, 0.94-1.02), mild preeclampsia (0.97, 0.92-1.02), and severe preeclampsia or haemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome (0.95, 0.86-1.05). Among 215 974 liveborn children, 108 350 were exposed to the vaccine. Vaccination was not associated with adverse infant outcomes and yielded a 72% (42-87%) effectiveness against laboratory-confirmed pertussis (9 vs. 32 events). DISCUSSION: Pertussis vaccination in pregnancy was effective in preventing infant pertussis and was not associated with adverse pregnancy or infant outcomes. Future studies should, however, examine whether other vaccines or the administration of multiple vaccines during pregnancy pose an increased maternal risk of hypertensive disorders in pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Denmark. Electronic address: helene.christine.kildegaard.jensen@regionh.dk.
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Denmark.
- Department of Infectious Disease Epidemiology & Prevention, Statens Serum Institut, Copenhagen, Denmark.
- Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark.
- Department of Gynaecology, Fertility & Obstetrics, Copenhagen University Hospital Rigshospitalet, Copenhagen Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Zitieren
APA
Kildegaard, H., Jensen, A., Andersen, P. H. S., Dalby, T., Gram, M. A., Lidegaard, Ø., & Stensballe, L. G. (2025). Safety of pertussis vaccination in pregnancy and effectiveness in infants: a Danish national cohort study 2019–2023. Clinical Microbiology and Infection, 31(6), 995-1002. https://doi.org/10.1016/j.cmi.2025.03.014
Vancouver
Kildegaard H, Jensen A, Andersen PHS, Dalby T, Gram MA, Lidegaard Ø, et al. Safety of pertussis vaccination in pregnancy and effectiveness in infants: a Danish national cohort study 2019–2023. Clinical Microbiology and Infection. 2025;31(6):995-1002. doi:10.1016/j.cmi.2025.03.014
BibTeX
@article{Kildegaard2025,
author = {Kildegaard, Helene and Jensen, Andreas and Andersen, Peter H S and Dalby, Tine and Gram, Mie Agermose and Lidegaard, Øjvind and Stensballe, Lone Graff},
title = {Safety of pertussis vaccination in pregnancy and effectiveness in infants: a Danish national cohort study 2019–2023},
journal = {Clinical Microbiology and Infection},
year = {2025},
volume = {31},
number = {6},
pages = {995--1002},
doi = {10.1016/j.cmi.2025.03.014}
}
EUVIMED